Literature DB >> 31161335

Higher expression of cation transport regulator-like protein 1 (CHAC1) predicts of poor outcomes in uveal melanoma (UM) patients.

Yanchen Liu1, Mengyun Li1, Danping Shi1, Yuguang Zhu2.   

Abstract

OBJECTIVE: The purpose of our present study was to investigate the expression of cation transport regulator-like protein 1 (CHAC1) in uveal melanoma (UM) tissues and its function in UM progression.
METHODS: The mRNA expression of CHAC1 in UM tissues and its prognostic value were investigated based on Gene Expression Omnibus database and The Cancer Genome Atlas database. SP6.5 and M23 UM cell lines with depleted CHAC1 were constructed using small interfering RNA. The viability and migration ability of SP6.5 and M23 UM cells were determined by MTT and wound healing assays, respectively. Western blot was conducted to test the influences of CHAC1 depletion on PI3K signaling pathway.
RESULTS: Higher expression of CHAC1 was observed in the UM tissues from patients with liver metastases compared to that from patients without metastases. High CHAC1 expression was correlated with poor prognostic and was an independent predictor for UM patients. Depletion of CHAC1 remarkably inhibited the proliferation and motility of SP6.5 and M23 UM cells. Moreover, the ratios of p-AKT/AKT and p-mTOR/mTOR were reduced notably after silencing CHAC1.
CONCLUSIONS: Our results suggested that CHAC1 functioned as a facilitator in UM cell proliferation and migration and possessed the potential to be a predictor as well as a therapeutic target for UM patients.

Entities:  

Keywords:  CHAC1; Migration; PI3K signaling pathway; Prognosis; Uveal melanoma

Mesh:

Substances:

Year:  2019        PMID: 31161335     DOI: 10.1007/s10792-019-01129-1

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  24 in total

Review 1.  Uveal melanoma.

Authors:  Francesco Spagnolo; Graziano Caltabiano; Paola Queirolo
Journal:  Cancer Treat Rev       Date:  2012-01-24       Impact factor: 12.111

2.  Progress in the management of patients with uveal melanoma. The 2012 Ashton Lecture.

Authors:  B Damato
Journal:  Eye (Lond)       Date:  2012-06-29       Impact factor: 3.775

3.  The CHAC1-inhibited Notch3 pathway is involved in temozolomide-induced glioma cytotoxicity.

Authors:  Peng-Hsu Chen; Wan-Lin Shen; Chwen-Ming Shih; Kuo-Hao Ho; Chia-Hsiung Cheng; Cheng-Wei Lin; Chin-Cheng Lee; Ann-Jeng Liu; Ku-Chung Chen
Journal:  Neuropharmacology       Date:  2016-12-13       Impact factor: 5.250

4.  Development of a novel prognostic score for breast cancer patients using mRNA expression of CHAC1.

Authors:  Beate Jahn; Marjan Arvandi; Ursula Rochau; Heidi Fiegl; Georg Goebel; Christian Marth; Uwe Siebert
Journal:  J Comp Eff Res       Date:  2017-09-19       Impact factor: 1.744

5.  Upregulation of LYAR induces neuroblastoma cell proliferation and survival.

Authors:  Yuting Sun; Bernard Atmadibrata; Denise Yu; Matthew Wong; Bing Liu; Nicholas Ho; Dora Ling; Andrew E Tee; Jenny Wang; Imran N Mungrue; Pei Y Liu; Tao Liu
Journal:  Cell Death Differ       Date:  2017-07-07       Impact factor: 15.828

6.  Activation of the ATF6, XBP1 and grp78 genes in human hepatocellular carcinoma: a possible involvement of the ER stress pathway in hepatocarcinogenesis.

Authors:  Masahiro Shuda; Nobuo Kondoh; Nobuo Imazeki; Kenji Tanaka; Tetsuya Okada; Kazutoshi Mori; Akiyuki Hada; Masaaki Arai; Toru Wakatsuki; Osamu Matsubara; Naoki Yamamoto; Mikio Yamamoto
Journal:  J Hepatol       Date:  2003-05       Impact factor: 25.083

7.  CHAC1/MGC4504 is a novel proapoptotic component of the unfolded protein response, downstream of the ATF4-ATF3-CHOP cascade.

Authors:  Imran N Mungrue; Joanne Pagnon; Omid Kohannim; Peter S Gargalovic; Aldons J Lusis
Journal:  J Immunol       Date:  2009-01-01       Impact factor: 5.422

8.  Elevated mRNA expression of CHAC1 splicing variants is associated with poor outcome for breast and ovarian cancer patients.

Authors:  G Goebel; R Berger; A M Strasak; D Egle; E Müller-Holzner; S Schmidt; J Rainer; E Presul; W Parson; S Lang; A Jones; M Widschwendter; H Fiegl
Journal:  Br J Cancer       Date:  2011-11-22       Impact factor: 7.640

Review 9.  Uveal Melanoma: Current Trends in Diagnosis and Management.

Authors:  Berçin Tarlan; Hayyam Kıratlı
Journal:  Turk J Ophthalmol       Date:  2016-06-06

10.  Upregulation of BCL2 19 kD Protein-Interacting Protein 3 (BNIP3) is Predictive of Unfavorable Prognosis in Uveal Melanoma.

Authors:  Zhongming Jiang; Fenghua Yu; Man Li
Journal:  Med Sci Monit       Date:  2018-07-08
View more
  5 in total

1.  Prognostic significance of CHAC1 expression in breast cancer.

Authors:  Vikrant Mehta; Jaipal Meena; Harit Kasana; Anjana Munshi; Harish Chander
Journal:  Mol Biol Rep       Date:  2022-06-21       Impact factor: 2.742

Review 2.  Recent advances in understanding the role of HES6 in cancers.

Authors:  Imène Krossa; Thomas Strub; Arnaud Martel; Sacha Nahon-Esteve; Sandra Lassalle; Paul Hofman; Stéphanie Baillif; Robert Ballotti; Corine Bertolotto
Journal:  Theranostics       Date:  2022-05-20       Impact factor: 11.600

3.  Ferroptosis-related gene CHAC1 is a valid indicator for the poor prognosis of kidney renal clear cell carcinoma.

Authors:  Deng Li; Shiwei Liu; Jie Xu; Lei Chen; Chaoliang Xu; Feiteng Chen; Zijie Xu; Yu Zhang; Shujie Xia; Yi Shao; Yi Wang
Journal:  J Cell Mol Med       Date:  2021-03-16       Impact factor: 5.295

Review 4.  Prognostic Biomarkers in Uveal Melanoma: The Status Quo, Recent Advances and Future Directions.

Authors:  Nuno Jorge Lamas; Arnaud Martel; Sacha Nahon-Estève; Samantha Goffinet; Adam Macocco; Corine Bertolotto; Sandra Lassalle; Paul Hofman
Journal:  Cancers (Basel)       Date:  2021-12-25       Impact factor: 6.639

5.  Construction of an endoplasmic reticulum stress-related gene model for predicting prognosis and immune features in kidney renal clear cell carcinoma.

Authors:  Yuanhao Shen; Yinghao Cao; Lei Zhou; Jianfeng Wu; Min Mao
Journal:  Front Mol Biosci       Date:  2022-09-02
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.